Lawyer, Patent Attorney, Trade Mark Attorney
BScLLB(Hons), MIP, GDLP
Bachelor of Science (Molecular Genetics),
Bachelor of Laws (with Honours),
Graduate Diploma of Legal Practice, Masters of Industrial Property
Underpinning Naomi’s legal work is a deep understanding of the pharma/biopharma industries and technologies, resulting from first hand experience and knowledge as VP of IP in-house, and Partner at a top-tier international law firm.
Naomi Pearce is a strategic, commercially astute, patent lawyer, patent attorney and trade mark attorney, with over 20 years experience in global pharma and biopharma industries. Naomi has a demonstrated ability to find creative, pragmatic solutions to legal/patent “problems” and is recognised by industry as a leader in global patent strategies.
For more than a decade, Naomi built and led IP teams in-house for global pharma/biopharma giants Mylan and Pfizer (then Hospira/Mayne Pharma).
Naomi returned to Australia at VP of IP level, with incomparable global pharma/biopharma patent experience.
With global responsibility for all IP/legal aspects of a suite of pharma and biopharma products, and with a team around the world, Naomi:
developed & implemented creative, global, product specific, IP strategies; and
influenced global health policies and law by supporting lobbying efforts regarding: the regulation of biosimilars around the world, patent law reform, and international trade agreements.
Naomi’s decade of global biosimilars responsibility at Pfizer and at executive level at Mylan put her ahead of the curve on issues relating to the global development and launch of biosimilars. Naomi is a biosimilars IP trailblazer.
Naomi was responsible for the IP/legal strategies supporting the successful and timely launch of the world’s first two biosimilar mAb products, two of the first biosimilar protein products, and many others. She also developed the IP strategies which resulted in the successful outcome in the world’s first Court decision regarding biosimilar mAb patent issues.
Naomi is a patent litigator. As external counsel, Naomi manages AU patent litigations in the Australian Courts and proceedings before the APO, and is a key team member in litigations with global footprint. As in-house counsel Naomi managed multiple US Hatch Waxman litigation, US PMNOC strategies, CA PMNOC proceedings, patent litigations in AU, HK, UK, DE, NE, NZ, PO, IE (among other regions), and patent oppositions before EPO, AU and NZ. Naomi's clients use her global litigation experience to assist them manage global litigations with many moving parts, and to act as "external in-house counsel" for overseas litigations where required.
Returning to external practice, Naomi joined K&L Gates as the first patents Partner in the Sydney team in 2015 and Co-Chaired the first Global Patents Pharma/Biopharma Industry Group, a global team of partners focussed on those industries.
Naomi was the first Chair of the Legal Working Group of the Generic and Biosimilar Medicines Association of Australia (GBMA), and for many years was actively involved with various committees of the European Generics Association (EGA), the US Generic Pharmaceuticals Association (GPhA), and the US Cooalition for a Competitive Pharmaceutical Market (CCPM).
Naomi is a regular international speaker on IP issues relating to small molecule and biosimilar medicines.